5 big analyst AI moves: Apple lifted to Buy, AI chip bets reassessed
Zuraiz Chaudhary, Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer at Turn Therapeutics Inc. (NASDAQ:TTRX), acquired 5,050 shares of common stock on October 23, 2025. The shares were purchased at a price of $4.95, totaling $24,997.
In other recent news, Turn Therapeutics, a clinical-stage biotechnology company, has announced the appointment of Arthur Golden to its Board of Directors. Golden brings extensive experience to the role, with over 40 years in corporate law, governance, and strategic advisory work. He is currently Senior Counsel at Davis Polk & Wardwell LLP, a position he took after more than 40 years as a partner at the firm. Additionally, Golden recently concluded a 24-year tenure as a Director at Emerson Electric, where he chaired the Corporate Governance and Finance Committees and served on the Executive Committee. This appointment is seen as a strategic move by Turn Therapeutics to strengthen its governance and strategic advisory capabilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.